Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The discovery that the apolipoprotein E (apoE) ε4 allele is genetically linked to both sporadic and familial late-onset Alzheimer's disease (AD) raises the possibility that a dysfunction of the lipid transport system could seriously affect lipid homeostasis in the brain of AD subjects. The presence of the ε4 allele has been associated with lower levels of apoE in both serum and brain tissues of normal and AD subjects. In an attempt to reverse the apoE deficit in AD, we identified and characterized several apoE inducer agents using a low-throughput in vitro screening assay. The most promising of these compounds is called probucol. Administration of probucol, an old cholesterol-lowering drug, in a pilot trial in mild-to-moderate sporadic AD led to a significant increase in cerebrospinal fluid (CSF) apoE levels and a decrease in CSF in both phosphorylated tau 181 and beta-amyloid 1-42 concentrations without significant modifications of lipid hydroperoxide levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“…of the APOJ, CR1, PICALM, BIN1, ABCA7, and CD33 loci as new genetic determinants of AD (in addition to the wellestablished apoε4 variant) (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010) with at least 1 independent genome-wide association study (GWAS) replication for…”
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Molecular mechanism and physiological functions of clathrin-mediated endocytosis
McMahon, H. T., & Boucrot, E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3151 · Cited by 2,223
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“…1996; Slooter et al., 1997), amyotrophic lateral sclerosis, or other type of neurode-generative disease (Hogh et al., 2000; Sorbi et al., 1995), apoE ε2 allele was found to be protective against several neurodegenerative diseases, including sporadic and familial late-onset AD (Corder et al., 1994).”
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 3×
“…examined and many have been proposed as putative genetic determinants of sporadic AD, none (except apoE) has yet been definitively accepted as such, in view of the lack of robustness of the associations observed between independent populations (Bertram et al., 2007 and http:// www.alzgene.org).”
InfluentialThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“This hypothesis has been reviewed extensively recently (Kim et al., 2009) and will not be addressed in the present review.”
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 1×
“ApoE ε4 allele was shown to be strongly associated with the familial and sporadic forms of AD (Poirier et al., 1993; Strittmatter et al., 1993).”
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108 · cited 1×
“ApoE ε4 allele was shown to be strongly associated with the familial and sporadic forms of AD (Poirier et al., 1993; Strittmatter et al., 1993).”
Self-citationApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 1×
“More recently, the Liver X receptor LXR) agonist T0901317 (Riddell et al., 2007) and the Retinoid X receptor (RXR) agonist bexarotene (Cramer et al., 2012) were both identified as modulators of the signaling cascade that regulate the acute synthesis of apoE, ABCA1/G1, and the LDL receptor family in…”
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714 · cited 1×
“The semidominant nature of the association between the apoε4 allele and sporadic AD has been firmly established only recently (Genin et al., 2011).”
Brecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G.-Q., Xu, Q., Dee Fish, J., Wyss-Coray, T., Buttini, M., Mucke, L., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4315-03.2004 · Cited by 403 · cited 1×
“The second hypothesis implicates tau protein metabolism and assumes that apoE is released in the cytoplasmic compartment, where it interferes directly with the cytoskeletal architecture of neurons (Brecht et al., 2004).”
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 2×
“ApoE and apoJ (also referred to as clusterin) were originally cloned in the early 1990s from a complementary DNA differential screening of messenger RNAs (mRNAs) expressed in the AD hippocampus (May et al., 1990).”
Self-citationArendt, T., Schindler, C., Brückner, M. K., Eschrich, K., Bigl, V., Zedlick, D., & Marcova, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00516.1997 · Cited by 319 · cited 2×
“ApoE ε4 carriers were also shown to exhibit poor synaptic remodeling and defective compensatory plasticity in vulnerable brain areas in AD (Arendt et al., 1997; Beffert et al., 1998), particularly in cholinergic-rich region (Poirier et al., 1995).”
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274 · cited 2×
“…(Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease Neuroimaging Initiative [ADNI]) in humans and in fresh brain tissues from apoE ε4 knock-in mice (Bales et al., 2009; Sullivan, 2009) when using liquid chromatography followed by tandem mass spectrometry (LC/MS/MS) quantitative methodology.”
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.01.011 · Cited by 244 · cited 3×
“More recently, the Liver X receptor LXR) agonist T0901317 (Riddell et al., 2007) and the Retinoid X receptor (RXR) agonist bexarotene (Cramer et al., 2012) were both identified as modulators of the signaling cascade that regulate the acute synthesis of apoE, ABCA1/G1, and the LDL receptor family in…”
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
Bertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00097-c · Cited by 210 · cited 1×
“…is true for blood (Gupta et al., 2011; Panza et al., 2003; Poirier, 2005; Soares et al., 2012; Utermann, 1985), brain tissues (Beffert et al., 1999; Bertrand et al., 1995) (Glockner et al., 2002), and CSF (Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease Neuroimaging Initiative [ADNI]) in…”
Self-citationCerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
Cruchaga, C., Kauwe, J. S. K., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A. M., Holtzman, D. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds296 · Cited by 207
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging
Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c352 · Cited by 149 · cited 1×
“This is true for blood (Gupta et al., 2011; Panza et al., 2003; Poirier, 2005; Soares et al., 2012; Utermann, 1985), brain tissues (Beffert et al., 1999; Bertrand et al., 1995) (Glockner et al., 2002), and CSF (Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease Neuroimaging Initiative…”
Apolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144 · cited 2×
“Whereas the apoE ε4 allele is associated with poor clinical outcome in patients with Parkinson’s disease (Li et al., 2004), stroke (Nicoll et al., 1996; Slooter et al., 1997), amyotrophic lateral sclerosis, or other type of neurode-generative disease (Hogh et al., 2000; Sorbi et al., 1995), apoE ε2…”
Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142 · cited 2×
“This is true for blood (Gupta et al., 2011; Panza et al., 2003; Poirier, 2005; Soares et al., 2012; Utermann, 1985), brain tissues (Beffert et al., 1999; Bertrand et al., 1995) (Glockner et al., 2002), and CSF (Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease Neuroimaging Initiative…”
Self-citationPrice, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138
Reduced levels of human apoE4 protein in an animal model of cognitive impairment
Sullivan, P. M., Han, B., Liu, F., Mace, B. E., Ervin, J. F., Wu, S., Koger, D., Paul, S., & Bales, K. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.011 · Cited by 113
Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice
Krzywkowski, P., Ghribi, O., Gagné, J., Chabot, C., Kar, S., Rochford, J., Massicotte, G., & Poirier, J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00061-5 · Cited by 74 · cited 2×
“Furthermore, long-term potentiation (Krzywkowski et al., 1999), synaptic plasticity, and terminal proliferation (Champagne et al., 2005; Veinbergs and Masliah, 1999) are markedly compromised in apoE-deficient mice in presence of abnormally high concentrations of tau phosphorylation (Gordon et al.,…”
Self-citationDifferential neurotrophic effects of apolipoprotein E in aged transgenic mice.
Veinbergs, I., Mallory, M., Mante, M., Rockenstein, E., Gilbert, J. R., & Masliah, E. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00243-8 · Cited by 46 · cited 2×
“The complete absence of apoE in the knockout mice is associated with progressive age-related cognitive deficit in the Morris swim maze (Champagne et al., 2002; Davignon et al.,1982; Oitzl et al., 1997; Veinbergs et al., 1999), a marked loss of cholinergic innervation with age (Kleifeld et al.”
Apolipoprotein E Mutants, Hyperlipidemia and Arteriosclerosis
Utermann, G. (1985) · Drugs Affecting Lipid Metabolism VIII · doi:10.1007/978-1-4613-2459-1_14 · Cited by 24 · cited 2×
“This is true for blood (Gupta et al., 2011; Panza et al., 2003; Poirier, 2005; Soares et al., 2012; Utermann, 1985), brain tissues (Beffert et al., 1999; Bertrand et al., 1995) (Glockner et al., 2002), and CSF (Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease Neuroimaging Initiative…”
Cited by
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
“ApoE is additionally the major cholesterol transporter within the brain and appears to drive AD by multiple mechanisms that, as discussed below, includes reduced A degradation [47, 51].”
Background
Metadata
- Authors
- Poirier, J., Miron, J., Picard, C., Gormley, P., Théroux, L., Breitner, J., & Dea, D.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 35
- Pages
- S3-S10
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2129884198
- Cited by
- 98
- References
- 28
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.